Introduction
COVID-19 associated mucormycosis (CAM) is the result of the severe immunosuppression caused by COVID-19 and its management1. The first series of CAM was published in February 20212, since then there is an upsurge of these cases. The target group for CAM includes patients with a history of COVID-19, corticosteroid therapy, and uncontrolled blood sugars. These patients with alarming signs and symptoms should be considered for comprehensive evaluation3. The nasal cavity is the first point of contact and the fungus harboring the nasal cavity makes DNE an important tool of diagnosis. But changing trends and varied presentation of the disease in this epidemic include patients with minimal signs instead of established red flag symptoms. DNE in such cases is normal. The early stages of CAM need not have necrosis, discoloration, or blackening in the nasal cavity (Figure 1-a,b,c,d). The limitation of endoscopy is in evaluation of the disease beyond the confinements of the nasal cavity. Then comes the role of imaging and biopsy in making an early and accurate diagnosis4.
This study was designed to determine the sensitivity and diagnostic accuracy of endoscopy and imaging in comparison to potassium hydroxide calcofluor white mount KOH mount and correlating them. This will help to formulate an ideal diagnostic strategy in suspected cases of invasive fungal sinusitis.